ClinicalTrials.gov 临床试验·· 28 天前精选AI 评分42
II期试验在婴儿新诊断KMT2A重排或非重排白血病中测试化疗联合venetoclax和/或blinatumomab
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
AI 导读
一项II期试验正在评估在常规化疗基础上加用venetoclax和/或blinatumomab,治疗新诊断的KMT2A基因重排(KMT2A-R)或非重排(KMT2A-G)急性淋巴细胞白血病(ALL)婴儿。Venetoclax属于Bcl-2抑制剂,blinatumomab为单克隆抗体,研究将考察这一联合方案的安全性和有效性。
推荐理由
该试验针对婴儿KMT2A重排或非重排ALL,在标准化疗基础上加用venetoclax和/或blinatumomab,读者可了解这一人群的联合治疗探索方向。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov